Investigational drug · Phase 2
MT101-5
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Parkinson's Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "MT101-5"
First trial start
2027
Sep 2027
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MT101-5", any sponsor or status.
Conditions studied
As listed on its trial records.
- Parkinson's Disease
Approved drugs for the same conditions: Parkinson's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "MT101-5" as an intervention, largest first.
- A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's DiseasePivotal-lookingNot yet recruiting
Mthera Pharma Co., Ltd.Industry
NCT06175767 · 120 participants (planned) · Start Sep 2027 · Primary completion Jan 2028
Drug: MT101-5 · For: Parkinson's Disease
Mthera Pharma Co., Ltd.Industry
NCT05844787 · 48 participants · Start Jul 11, 2022 · Primary completion Feb 23, 2023
Drug: MT101-5 · For: Parkinson's Disease
Sites: Secaucus, New Jersey
Newest research
PubMed records naming it or its code names, newest first.
- De novo identification of potent ingredients for proteasome activation in MT101-5 using an AI-driven approach.
Kim S, Han M, Kim SW, et al. · Biomed Pharmacother 2026
- Inhibition of α-synuclein aggregation by MT101-5 is neuroprotective in mouse models of Parkinson's disease.
Kim S, Choi JG, Kim SW, et al. · Biomed Pharmacother 2022
Also in development for Parkinson's Disease
- PrasinezumabRO7046015, PRX002Phase 33 trials
Roche (Genentech) · Parkinson's Disease, Parkinsons Disease
- CVN424Phase 32 trials
Cerevance · Parkinson Disease, Parkinson's Disease
- GM1Phase 32 trials
Qilu Pharmaceutical Co., Ltd. · Chemotherapy-induced Peripheral Neuropathy (CIPN), Parkinson's Disease
- iPSChuman allogeneic induced pluripotent stem cell -derived dopaminergic neural progenitor cell, Allogeneic Human Induced Pluripotent Stem Cell -Derived Motor Neuron Progenitor CellsPhase 23 trials
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. · Spinal Cord Injury, Safety, Efficacy
- RO7568282Phase 22 trials
Roche (Genentech) · Parkinson's Disease, Alzheimer's Disease
- BIA 28-6156Phase 21 trial
Bial R&D Investments, S.A. · Parkinson's Disease
- ND0612ND0612HPhase 21 trial
NeuroDerm Ltd. · Parkinson's Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.